Biohaven
Biohaven works on 12 rare diseases tracked on Trial Friend, including Amyotrophic Lateral Sclerosis, Inherited Erythromelalgia, Focal Epilepsy and 9 more, with 8 active clinical trials (3 recruiting).
Biohaven traces its origin to one of the more unusual deals in recent biotech history. Founder and CEO Dr. Vlad Coric, a Yale psychiatrist who spent years working on neuropsychiatric and neurodegenerative drugs, licensed the migraine compound rimegepant from Bristol-Myers Squibb in 2016 and built it, as Nurtec ODT, into one of the fastest-growing branded migraine pills in the United States. In 2022, Pfizer paid $11.6 billion to acquire the original Biohaven and keep Nurtec for its migraine franchise. Vlad and his team kept everything else, spinning the remaining pipeline out as a new public company in October 2022. The new Biohaven now trades on the NYSE under the ticker BHVN and is based in New Haven, Connecticut.
The largest part of today's pipeline is a new class of drugs in immunology, designed to clear disease-driving proteins from the body. The platforms are called MoDE and TRAP, both licensed from Yale University in 2021, and the simplest way to describe what they do is that they grab onto specific antibodies or proteins floating in the blood, the kind that drive autoimmune disease, and pull them into the body's natural cleanup pathway to be destroyed. The two most advanced degrader programs moved into late-stage testing in 2026: BHV-1300 began a Phase 3 pivotal trial in Graves' disease, dosing its first patient in June 2026 after early studies showed it could lower the disease-driving thyroid antibody by more than 80%, and BHV-1400 is expected to begin its pivotal trial in IgA nephropathy in the second half of 2026. On October 8, 2026, Biohaven licensed BHV-1300 and 2 follow-on IgG degraders to Ono Pharmaceutical for Japan, South Korea, Taiwan and Southeast Asia, keeping all rights in the US, Europe and China. Earlier-stage degrader candidates target IgG4-mediated disease (BHV-1450), peripartum cardiomyopathy (BHV-1600), membranous nephropathy (BHV-1420), and other pathogenic proteins, with nearly 200 people dosed across the degrader platform to date. The platform's provenance also received a legal stamp in 2026: a federal jury found that Avilar Therapeutics and RA Capital had willfully misappropriated the Yale trade secret behind the MODA degradation technology, and on August 25, 2026 the court entered judgment awarding Biohaven and Yale a combined $4 million.
Beyond immunology, Biohaven is also running late-stage trials in two brain-related areas. Opakalim (BHV-7000) is in Phase 2/3 development for focal epilepsy and works by stabilizing electrical activity in the brain that drives seizures; RISE 3, one of its 2 pivotal studies, finished enrolling in June 2026, and Biohaven expects its topline results in the second half of 2026. BioPharma Dive reported on September 10, 2026 that the FDA placed the program on a partial clinical hold on September 4, and Fierce Biotech reported the same hold. The hold stops new patients from enrolling, including in RISE 2, while Biohaven provides more animal data on a substance the body makes when it breaks down the drug. People already in the trials keep taking it. On August 26, 2026, Biohaven granted SK Biopharmaceuticals an exclusive worldwide license to its Kv7 ion channel platform, including opakalim. Biohaven will receive $400 million in near-term cash plus development and regulatory milestones and royalties, and SK Biopharmaceuticals will take over Kv7 program costs and commercialization; the agreement is subject to antitrust clearance before it closes. Separately, BHV-8000 is in Phase 2/3 development for early Parkinson's disease and aims to dampen brain inflammation thought to contribute to disease progression. In oncology, two cancer drugs called antibody-drug conjugates (BHV-1510 and BHV-1530) are in Phase 1 trials for solid tumors, both now being tested in combination with Regeneron's Libtayo under clinical supply agreements, with updated BHV-1530 data expected at the ESMO cancer congress in October 2026. On September 28, 2026, Biohaven said BHV-1530 data were also chosen for an oral presentation at the EORTC-NCI-AACR Symposium.
The company has had recent setbacks worth noting. Troriluzole, a glutamate modulator that Biohaven had been developing for spinocerebellar ataxia, received an FDA Complete Response Letter in November 2025. Biohaven said it was formally requesting a meeting with the FDA. Neither Biohaven nor the FDA has said publicly whether that meeting took place or what came of it. It had already withdrawn its European application in March 2025. Taldefgrobep alfa, a myostatin inhibitor, missed its Phase 3 endpoint in spinal muscular atrophy and is now being studied in obesity, where it is designed to promote weight loss while preserving lean muscle; the Phase 2 obesity study finished enrolling in early 2026 and topline data is expected in the second half of 2026.
Biohaven Drug Pipeline
Biohaven has 8 active clinical trials across 3 development stages, with 3 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline counts the active and recruiting trials listed on this page, from ClinicalTrials.gov. For companies that work outside rare disease, we list only trials for rare diseases we track, so the company's full pipeline may be larger.
Biohaven Clinical Trials (8)
Active and recruiting clinical trials sponsored by Biohaven, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Biohaven. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Amyotrophic Lateral Sclerosis. Turn any of these off from the link in every email.
FDA-Approved Drugs
Biohaven Trial Locations
Biohaven clinical trials are running at 417 sites in 28 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (12)
Diseases targeted by Biohaven's clinical trial and drug development programs
Amyotrophic lateral sclerosis is a progressive neurodegenerative disease destroying motor neurons in the brain and spinal cord. This causes progressive weakness and paralysis of voluntary muscles whil...
Inherited erythromelalgia is a rare autosomal dominant pain disorder caused by gain-of-function mutations in the SCN9A gene, which encodes the Nav1.7 voltage-gated sodium channel. Patients experience ...
Focal epilepsy is a neurological disorder characterized by recurrent seizures that originate in a specific area of the brain. It is the most common form of epilepsy in adults. Seizures may involve alt...
Graves' disease is the most common cause of hyperthyroidism, an autoimmune condition where antibodies stimulate the thyroid gland to produce excessive thyroid hormone. It can cause a wide range of sym...
IgA nephropathy is the most common primary glomerulonephritis worldwide, caused by abnormal IgA1 antibodies depositing in the kidney's mesangium, activating complement pathways and triggering inflamma...
Membranous nephropathy is a rare autoimmune kidney disease where the body's own antibodies attack proteins in the kidney's filtering units (glomeruli). This causes thickening of the filter membranes a...
Patient Resources
Organizations and resources related to Biohaven's rare disease focus areas
Frequently Asked Questions About Biohaven
Common questions about Biohaven's rare disease programs, clinical trials, and treatments.